About SRT > Strategy

Strategy

SRT’s business strategy employs gene replacement through gene therapy and gene expression correction through chromatin modification as the basis for treatments for orphan diseases. The company seeks to develop such treatments first in the United States and then to make them available in selected countries worldwide.

There are more than 6,000 recognized orphan diseases in the United States and nearly 300 FDA approved treatments. Some examples of widely known orphan diseases are thalassemia, sickle cell anemia, cystic fibrosis, and Huntington’s disease; additionally many forms of cancer are designated as orphan diseases. These diseases represent an unmet medical need and present an opportunity to companies such as SRT.

SRT’s long-term goal is to make its gene therapy available to β-Thalassemia and Sickle Cell Disease patients at affordable prices worldwide.

The key element of the SRT strategy is the accelerated development of its lead products. In addition, the company will build value through the emergence of additional products from its patent portfolio. Finally, SRT will maintain an ongoing effort to identify new opportunities through collaboration with leading universities.

The overall goal of SRT is to spend as little as possible on executive compensation and provide the safest and most affordable gene therapy to cure patients.